Last reviewed · How we verify
Psoriatic Arthritis and Ankylosing Spondylitis — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Induction- PF-06480605 150 mg SC Q4W | induction-pf-06480605-150-mg-sc-q4w | Pfizer | JAK inhibitor | JAK pathway |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 1 drug in Psoriatic Arthritis and Ankylosing Spondylitis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Psoriatic Arthritis and Ankylosing Spondylitis:
- Psoriatic Arthritis and Ankylosing Spondylitis treatment updates — RSS
- Psoriatic Arthritis and Ankylosing Spondylitis treatment updates — Atom
- Psoriatic Arthritis and Ankylosing Spondylitis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Psoriatic Arthritis and Ankylosing Spondylitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/psoriatic-arthritis-and-ankylosing-spondylitis. Accessed 2026-06-10.
Related
- Psoriatic Arthritis and Ankylosing Spondylitis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing